Perrigo’s Pivot To Building Brand Market Share Boosted With Opill OTC Oral Contraceptive Approval

Year after acquiring HRA, Perrigo makes preparations to launch arguably the most anticipated OTC switch in US pharma history, Opill with 0.075-mg norgestel. Analysts estimate $100m annual market for OTC birth control.

• Source: Shutterstock/FDA

Perrigo Company PLC has made notable progress before in its pivot from focusing its US OTC drug business on providing generic copies of OTC national brands to making and marketing national brands.

The transition’s biggest step to date came on 13 July with the Food and Drug Administration’s approval of the application...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

GSCF: ‘No One Size Fits All’ Solution To Tricky Sustainable Blister Pack Challenge

 
• By 

A series of research papers recently published by the Global Self-Care Federation indicate that industry will need to be pragmatic about alternatives to PVC in medicine blister packs.

Moberg Has US Ambitions For Novel Nail Fungus Treatment

 
• By 

Sweden's Moberg wants to introduce its onychomycosis treatment to the US but expects it will need to complete an additional study to win FDA approval.

People On The Move: Appointments At Enzymatica, Haleon, Futura

 
• By 

A round up of the latest moves in Europe's consumer health market: Enzymatica appoints CEO; Haleon hires DACH marketing chief; Futura confirms interim CEO.

Over The Counter: Turning Global Ambition Into Local Reality, With Haleon’s Jo Cooper

 
• By 

HBW Insight speaks to Haleon's UK & Ireland general manager Jo Cooper about how she plans to translate the firm's ambitious global growth strategy to a local context.

More from Business

Primatene Mist Sales Flat As Amphastar Plans Production Expansion To Support Pipeline

 

Amphastar plans three- to five-year expansion to quadruple production capacity for its US manufacturing operations at its Rancho Cucamonga, CA, headquarters. Primatene Mist Q2 sales reached $22.88m from $22.86m a year ago.

Complementary Medicine Move Paying Off For Galenica

 
• By 

Galenica's Swiss consumer health business Verfora is reaping the rewards of its expansion in the complementary medicine market with a solid showing in the first half of the year.

Over The Counter: Turning Global Ambition Into Local Reality, With Haleon’s Jo Cooper

 
• By 

HBW Insight speaks to Haleon's UK & Ireland general manager Jo Cooper about how she plans to translate the firm's ambitious global growth strategy to a local context.